Carbon Dioxide → [(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-5-methylnaphthalene-1-carboxylate

HRID 1877737

Reaktionsgleichung

Reaktionsgleichung von HRID 1877737
O=[CH:2][C@@H:3]([C@H:5]([C@@H:7]([C@@H:9]([CH2:11][OH:12])O)[OH:8])[OH:6])[OH:4].[C:13]([O-])(=O)[C:14]([CH3:16])=O.CC1(C)S[C@@H]2[C@H](N[C:29]([CH2:31][C:32]3[CH:33]=[CH:34][CH:35]=[CH:36][CH:37]=3)=[O:30])C(=O)N2[C@H]1C([O-])=O.[K+].C[C@@H]1O[C@@H:47]([O:49][C@H:50]2[C@H:55](O)[C@@H:54](O)[C@H:53](NC(N)=N)[C@@H:52](O)[C@@H:51]2NC(N)=N)[C@H:46]([O:67][C@@H:68]2[O:73][C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2NC)[C@@:45]1([OH:82])C=O.C[C@H](N)[C:85]([NH:87][C@H](C(O)=O)CCC(N)=O)=O.[C:98](=O)=O.CC[C:103]([O:105][C:106]1([C:113]2[CH:118]=[CH:117][CH:116]=CC=2)CCN(C)CC1)=[O:104]>>[CH3:13][C:14]1[C:37]2=[CH:36][CH:35]=[CH:34][C:33]([C:103]([O:105][C@H:106]3[C@H:51]([O:12][C@H:11]4[O:4][C@H:3]([CH3:2])[C@H:5]([OH:6])[C@H:7]([OH:8])[C@H:9]4[NH:87][CH3:85])[C:52]4=[CH:53][C:54]#[C:55][C@H:50]5[O:49][C@@:47]5([C@@H:46]5[O:67][C:68](=[O:73])[O:82][CH2:45]5)[C:116]#[C:117][C:118]4=[CH:113]3)=[O:104])=[C:32]2[CH:31]=[C:29]([O:30][CH3:98])[CH:16]=1

Komponenten

8

Edukt 7

HCID 280Carbon DioxideHCID 615834-propionyloxy-4-phenyl-N-methylpiperidineHCID 107526(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanalHCID 107735PyruvateHCID 123935L-Alanyl-L-GlutamineHCID 23664709Penicillin G PotassiumHCID 178484872HCID 178484872, Verbindung

Produkt 1

HCID 44581473[(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-5-methylnaphthalene-1-carboxylate

Versuchsvorschrift

Human cervix adenocarcinoma HeLa cells are maintained as exponentially growing monolayers in Dulbecco modified Eagle's minimum essential medium with 4.5 g/l glucose, 0.1 g/l pyruvate, 105 UI/I penicilline, 0.1 g/l streptomycine, 0.86 g/l Glutamax I and 10% v/v foetal calf serum (37° C., 5% CO2), without or with 5 μM DL-threo-1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol (PPMP) to inhibit Gb3 expression. When present, PPMP is introduced into pre-cultures for at least 6 days prior to cytotoxicity assays and is present for up to drug wash.

Aufarbeitung

  1. temperatureHuman cervix adenocarcinoma HeLa cells are maintained as exponentially growing monolayers in Dulbecco
  2. washwash

Quellen und Nachweise

ORD-Eintrag
ord-a449d31f377044ea8c25ee0c3d5d20a9
Quelldatensatz
uspto-grants-2012_11
Patentnummer
US08313731B2

Verknüpfte Notizen

Wird geladen…